Latest Financial Results
16 April 2025 – 1 mins read
LinkedIn
Facebook
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
13 February 2025 – 1 mins read
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
24 April 2024 – 1 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 29 Financial Results
27 October 2022
LinkedIn
Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance
Paris (France), 27 October 2022
28 July 2022
LinkedIn
Ipsen delivers strong H1 2022 results and upgrades its full-year guidance
Paris (France), 28 July 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022:
27 April 2022
LinkedIn
11 February 2022
LinkedIn
21 October 2021
LinkedIn
Your dedicated contacts
-
Khalid Deojee
Senior Manager, Investor Relations
